JAMA Cardiology | Original Investigation

Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease

Mark Trinder, MSc; Gordon A. Francis, MD; Liam R. Brunham, MD, PhD

IMPORTANCE Monogenic familial hypercholesterolemia (FH) is associated with lifelong elevations in low-density lipoprotein cholesterol (LDL-C) levels and increased risk of atherosclerotic cardiovascular disease (CVD). However, many individuals with hypercholesterolemia have a polygenic rather than a monogenic cause for their condition. It is unclear if a genetic variant for hypercholesterolemia alters the risk of CVD.

OBJECTIVES To assess whether a genetic variant for hypercholesterolemia alters the risk of atherosclerotic CVD and to evaluate how this risk compares with that of nongenetic hypercholesterolemia.

DESIGN, SETTING, AND PARTICIPANTS In this genetic-association, case-control, cohort study, individuals aged 40 to 69 years were recruited by the UK Biobank from across the United Kingdom between March 13, 2006, and October 1, 2010, and followed up until March 31, 2017. Genotyping array and exome sequencing data from the UK Biobank cohort were used to identify individuals with monogenic (*LDLR, APOB,* and *PCSK9*) or polygenic hypercholesterolemia (LDL-C polygenic score >95th percentile based on 223 single-nucleotide variants in the entire cohort). The data were analyzed from July 1, 2019, to December 30, 2019.

MAIN OUTCOMES AND MEASURES The study investigated the association of genotype with the risk of coronary and carotid revascularization, myocardial infarction, ischemic stroke, and all-cause mortality among the overall study population and among participants with monogenic FH (n = 277), polygenic hypercholesterolemia (n = 2379), or hypercholesterolemia with undetermined cause (n = 2232) at comparable levels of LDL-C measured at study enrollment.

RESULTS For the 48 741 individuals with genotyping array and exome sequencing data, the mean (SD) age was 56.6 (8.0) years, and 54.5% were female (n = 26 541 of 48 741). A monogenic FH variant for hypercholesterolemia was found in 277 individuals (0.57%, 1 in 176 individuals). Participants with monogenic FH were significantly more likely than those without monogenic FH to experience an atherosclerotic CVD event at 55 years or younger (17 of 277 [6.1%] vs 988 of 48 464 [2.0%]; *P* < .001). Compared with the general population, both monogenic and polygenic hypercholesterolemia were associated with an increased risk of CVD events. Moreover, among individuals with comparable levels of LDL-C, both monogenic (hazard ratio, 1.93; 95% CI, 1.34-2.77; *P* < .001) and polygenic hypercholesterolemia (hazard ratio, 1.26; 95% CI, 1.03-1.55; *P* = .03) were significantly associated with an increased risk of CVD events in individuals with hypercholesterolemia without an identified genetic cause.

CONCLUSIONS AND RELEVANCE The findings of this study suggest that among individuals with hypercholesterolemia, genetic determinants of LDL-C levels may impose additional risk of CVD. Thus, understanding the possible genetic cause of hypercholesterolemia may provide important prognostic information to treat patients.

JAMA Cardiol. 2020;5(4):390-399. doi:10.1001/jamacardio.2019.5954 Published online February 12, 2020. Corrected on March 11, 2020. Editor's Note page 399
Supplemental content

Author Affiliations: Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada (Trinder, Francis, Brunham); Experimental Medicine Program, Department of Medicine, University of British Columbia. Vancouver, British Columbia, Canada (Trinder, Brunham); Department of Medicine, University of British Columbia, Vancouver, British Columbia. Canada (Francis. Brunham); Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada (Brunham).

Corresponding Author: Liam R. Brunham, MD, PhD, Centre for Heart Lung Innovation, University of British Columbia, 1081 Burrard St, Room 166, Vancouver, BC V6Z 1Y6, Canada (liam.brunham@ubc.ca).

jamacardiology.com

amilial hypercholesterolemia (FH) is an autosomal codominant genetic disorder with an estimated prevalence of 1 in 250 people.^{1,2} This disorder is caused by pathogenic variants in the *LDLR* (OMIM 606945), *APOB* (OMIM 107730), and *PCSK9* (OMIM 607786) genes that impair the clearance of low-density lipoproteins (LDLs) from the blood, leading to an increased risk of premature atherosclerotic cardiovascular disease (CVD).³⁻⁶ Despite its prevalence, FH remains underdiagnosed and undertreated.⁷

Compared with patients with elevated LDL cholesterol (LDL-C) levels and no FH-associated variant, those with a monogenic FH-associated variant have an approximately 2- to 3.5-fold increased risk of CVD.^{3,6} However, in many individuals with a phenotype of clinical FH, a monogenic FH-associated variant cannot be identified.⁸⁻¹⁴ These individuals may have a polygenic, environmental, or unknown monogenic cause for their hypercholesterolemia.

Polygenic hypercholesterolemia is estimated to account for approximately 20% to 30% of patients with clinical FH.^{15,16} The risk of CVD for individuals with polygenic hypercholesterolemia likely depends on the reference group. Genetic association and mendelian randomization studies have highlighted the important contribution of LDL-C polygenic scores to CVD risk among the general population.¹⁷⁻²¹ A recent study reported that among patients with clinical FH, an elevated LDL-C polygenic risk score was associated with increased CVD risk only in those individuals who also had monogenic FH.²² However, whether polygenic hypercholesterolemia vs hypercholesterolemia of unknown cause is associated with increased CVD risk remains unknown. The objective of this study was to assess how monogenic and polygenic causes of hypercholesterolemia are associated with the risk of CVD among the general population and how this risk compares with that in individuals with nongenetic hypercholesterolemia.

Methods

UK Biobank Cohort

This prospective cohort study included participants from the UK Biobank cohort study with genotyping array (n = 478 428) or genotyping array and exome sequencing (n = 48741) data (**Figure 1**).²³⁻²⁵ These participants were recruited by the UK Biobank from across the United Kingdom between March 13, 2006, and October 1, 2010, and followed up until March 31, 2017. The data were analyzed from July 1, 2019, to December 30, 2019. This study was approved by the UK Biobank and the clinical research ethics board of the University of British Columbia, Vancouver, Canada. All participants provided written informed consent to participate in the UK Biobank study.

Biochemical measurements, physical examination measurements, and medical histories were assessed at the time of study enrollment unless otherwise stated (eMethods and eTable 1 in the Supplement). In patients known to be receiving cholesterol level-lowering medication at the time of enrollment, baseline LDL-C levels were estimated by multiplying LDL-C levels during treatment by 1.43, corresponding to an estimated 30% reduction in the LDL-C level.^{1,26}

jamacardiology.com

Key Points

Question Does the risk of atherosclerotic cardiovascular disease (CVD) differ between individuals with monogenic hypercholesterolemia vs those with polygenic hypercholesterolemia?

Findings In this cohort study of 48 741 adults recruited by the UK Biobank, a monogenic cause for hypercholesterolemia was found in 277 participants (0.57%) and a polygenic cause in 2379 participants (4.9%). Both polygenic and monogenic causes of hypercholesterolemia appeared to be associated with an increased risk of CVD compared with hypercholesterolemia with an unknown genetic cause; however, monogenic hypercholesterolemia was associated with the greatest risk of CVD.

Meaning The findings of this study suggest that among individuals with comparable levels of low-density lipoprotein cholesterol, monogenic hypercholesterolemia may be associated with the greatest risk of CVD followed by polygenic hypercholesterolemia.

Definition of CVD Events

Cardiovascular disease events were defined as coronary and carotid revascularization, myocardial infarction, ischemic stroke, and all-cause mortality. The CVD events occurring before and after enrollment were included. Events occurring prior to enrollment were identified by either self-reported medical history and/or previous hospital admission documented in an electronic health record. Incident CVD events were defined by hospital admission with an electronic health record entry only. Cardiovascular disease events were defined by diagnosis codes from the International Classification of Diseases, Ninth Revision and International Classification of Diseases, Tenth Revision (eMethods in the Supplement).²³ Myocardial infarction, ischemic stroke, and mortality events were algorithmically defined by the UK Biobank. Coronary and carotid revascularization procedures were assessed using medical history and postenrollment operation codes according to the Office of Population Censuses and Surveys Classification of Interventions and Procedures, version 4 codes (eTable 2 in the Supplement).²³ Events were censored on the date of loss-tofollow-up or if individuals remained event-free up to March 31, 2017.

LDL-C Polygenic Score Construction

A data set of genotyped and imputed variants was obtained from the UK Biobank. Samples flagged for mismatch between reported sex and genetic sex or with more than 3 missing singlenucleotide variants (SNVs) of interest were excluded from analyses (Figure 1). Weighted LDL-C polygenic scores were calculated using data from the effect sizes of the 223 independent SNVs genome-wide association study discovery sample performed by the Global Lipids Genetics Consortium,^{17,27} which has been previously described (eTable 3 in the Supplement).²⁰ Polygenic scores were calculated using the formula Σ [β_x * SNV_x], where β_x is the effect size for the cholesterolincreasing allele and SNV_x is the number of LDL-C-increasing alleles (0, 1, or 2) for SNV_x (eMethods in the Supplement). K-means clustering was applied with k = 3 on the first 20 principal components of genetic ancestry to group individuals into



LDL-C indicates low-density lipoprotein cholesterol; SNV, single-nucleotide variant.

African, East Asian, and European superpopulations (eFigure 1 in the Supplement). An individual's LDL-C polygenic score percentile was ascertained relative to their respective UK Biobank superpopulation.

Annotation of UK Biobank Exome Sequencing Data for Monogenic FH-Associated Variants

A population-level functionally equivalent variant data set was available from the UK Biobank in PLINK format.²⁵ Variant filtering for this data set used a genotype depth filter of greater than 7 for SNVs and greater than 10 for indels and required at least 1 variant genotype to pass an allele balance (AB) filter (heterozygous SNV AB filter >0.15, heterozygous indel <0.20).

PLINK, version 1.9, was used to generate a project-level variant call file.²⁸ We used SnpEff to annotate the variant call file against the GRCh38.86 reference genome and provide gene-based functional predictions.²⁹ We used SnpSift to add dbNSFP^{30,31} and ClinVar³² annotations to variants.³³

Definitions of Monogenic FH, Polygenic Hypercholesterolemia, and Nongenetic Hypercholesterolemia

The *LDLR*, *APOB*, and *PCSK9* variants that were annotated in ClinVar as pathogenic or likely pathogenic for FH were considered monogenic FH-associated variants.^{3,32} The *LDLR* variants that were not annotated or had conflicting interpretations of pathogenicity annotations in ClinVar were considered monogenic FH-associated variants if they had a minor allele frequency of less than 0.001 and were predicted by SnpEff to result in a loss of gene function (stop gained, frameshift) or were missense variants predicted to be pathogenic by at least 5 of 6

bioinformatic tools (MetaSVM, LRT, Protein Variation Effect Analyzer, MutationTaster, Polyphen2, and Sorting Intolerant from Tolerant).^{3,22,34}

Participants with a 223 SNV LDL-C polygenic score higher than the 95th percentile were defined as having polygenic hypercholesterolemia. Participants with nongenetic hypercholesterolemia were identified by a 1:1 matching of individuals with polygenic hypercholesterolemia to those from the exome sequencing cohort who did not have monogenic FH based on LDL-C level, age, sex, the first 4 principal components of genetic ancestry, and genotyping array and batch. Matching was completed using the nearest neighbor algorithm in the MatchIt package, version 3.0.2, of R statistical software (R Core Team).

Statistical Analyses

Data were analyzed from July 1, 2019, to December 30, 2019, using R version 3.5.1, and χ^2 tests were used for contingency analyses. For comparison of 2 groups, normally distributed data were analyzed with an unpaired, 2-tailed *t* test, and non-normally distributed data were analyzed with a Mann-Whitney *U* test. For comparison of more than 2 groups, normally distributed data were analyzed with 1-way analysis of variance (with Tukey multiple comparison post hoc tests), and non-normally distributed data were analyzed with Kruskal-Wallis tests (with Dunn multiple comparison post hoc tests).

Multivariable linear regression models were used to assess the correlation between LDL-C levels and polygenic scores and were adjusted for age, sex, the first 4 principal components of genetic ancestry, and genotyping array and batch. Time-to-event analyses were analyzed with the Survival package, version 2.43-3, for R with Peto and Peto tests. *P* values from pairwise Peto and Peto tests of more than 2 groups were adjusted using the Benjamini-Hochberg correction. Cox regression models were used and adjusted for age, sex, the first 4 principal components of ancestry, and genotyping array and batch. When explicitly indicated, Cox regression models were additionally adjusted for LDL-C levels. Statistical significance was claimed when 2-sided *P* values were < .05.

Results

Association of LDL-C Polygenic Score With CVD Risk

Individuals with genotyping array data in the UK Biobank cohort study were included in the present study to assess whether LDL-C polygenic scores are associated with measured levels of LDL-C and risk of CVD (Figure 1 and eTable 4 in the Supplement). For the 478 428 individuals with genotype array data at the time of enrollment, the mean (SD) age was 56.6 (8.1) years, and 54.2% were female (n = 259 400 of 478 428). Other characteristics are provided in eTable 4 in the Supplement. There were considerable differences in the distribution of LDL-C polygenic scores among ancestral superpopulations (Figure 2A). The LDL-C polygenic scores were notably associated with baseline LDL-C levels (in milligrams per deciliter [to convert to millimoles per liter, multiply by 0.0259]) for individuals of African (multiple $R^2 = 0.04$; β [SE] = 17.40 [1.91]; P < .001) (n = 4680), East Asian (multiple $R^2 = 0.06$; β [SE] = 21.73 [1.25]; P < .001) (n = 10640), and European (multiple $R^2 = 0.09$; β [SE] = 28.01 [0.18]; P < .001) (n = 439 871) genetic ancestry (Figure 2B). Among the overall cohort, the correlation between LDL-C levels and LDL-C polygenic scores was comparable with the subgroup analysis restricted to individuals of European genetic ancestry (multiple $R^2 = 0.09$; β [SE] = 27.78 [0.18]; P < .001) (n = 455191).

The percentage of variance of LDL-C levels explained by the LDL-C polygenic score was assessed using stepwise addition of the 223 SNVs into multivariable linear regression models, with LDL-C levels used as the dependent variable. The percentage of variance in LDL-C levels explained by the inclusion of SNVs displayed notable saturation after 75 SNVs (9.61% variance explained) (eFigure 2 in the Supplement). An exponential plateau model of the data estimated that the maximum variance in LDL-C levels explained would be 10.19% (95% CI, 10.16-10.24; $R^2 = 0.97$). Similar predictions were made when analyses were restricted to individuals with European genetic ancestry (eFigure 2 in the Supplement). These results suggest that incorporation of a greater number of SNVs in the LDL-C polygenic score would be unlikely to provide statistically significant improvement to the predictive ability of the LDL-C polygenic scores.

Increasing LDL-C polygenic score percentile was associated with a dose-dependent increase in CVD risk among the overall cohort (test for trend, P < .001) (Figure 2C). Specifically, the 10th decile of the LDL-C polygenic score percentile was associated with the greatest risk of CVD compared with the first decile of the LDL-C polygenic score (adjusted hazard ratio [aHR], 1.35; 95% CI, 1.30-1.40; P < .001). These results were consistent in subgroup analyses consisting of individuFigure 2. Low-Density Lipoprotein Cholesterol (LDL-C) Polygenic Scores and LDL-C Levels and Risk of Cardiovascular Disease (CVD) Among all Individuals in the Genotyping Array Cohort



B Association between LDL-C polygenic store and LDL-C level



C Adjusted HRs for composite CVD events

Decile	No. of Events/ Total No.	aHR (95% CI)	Favors Lower Risk	Favors Higher Risk
1	4189/47841	1 [Reference]		
2	4349/47843	1.05 (1.00-1.09)		-
3	4433/47842	1.07 (1.02-1.11)		-
4	4600/47843	1.11 (1.07-1.16)		- -
5	4705/47842	1.15 (1.10-1.20)		
6	4696/47844	1.14 (1.10-1.19)		
7	4865/47843	1.18 (1.14-1.23)		-#-
8	4942/47842	1.21 (1.16-1.26)		-
9	5072/47843	1.25 (1.20-1.31)		
10	5397/47845	1.35 (1.30-1.40)		-
			0.5 Adjust	1 2 ed HRs

A, The distribution of LDL-C polygenic scores is depicted for the African, East Asian, and European ancestral superpopulations. B, The linear association between LDL-C polygenic scores and LDL-C levels (to convert to millimoles per liter, multiply by 0.0259) are depicted. Lines depict linear regression analyses segregated by ancestral superpopulation. C, The adjusted hazard ratios (aHRs) with 95% Cls for composite CVD events of myocardial infarction, coronary or carotid revascularization, ischemic stroke, or all-cause mortality are depicted for each decile of LDL-C polygenic score percentile (percentiles are calculated relative to each individual's ancestral superpopulation). Hazard ratios were adjusted for age, sex, genotyping array and/or batch, and the first 4 principal components of ancestry.

als of European (test for trend, P < .001; n = 462 236) and East Asian (test for trend, P = .004; n = 11 220) genetic ancestry (eFigures 3 and 4 in the Supplement). However, the cohort was

Figure 3. Monogenic Familial Hypercholesterolemia (FH)-Associated Variants and Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Level









A, Density plot shows the distribution of LDL-C levels (to convert to millimoles per liter, multiply by 0.0259) at enrollment between individuals with an FH-associated variant (mono-). B, The LDL-C levels are depicted for individuals with an FH-associated variant classified as likely pathogenic or pathogenic in ClinVar, an FH-associated variant predicted to be pathogenic, and individuals with no detected FH-associated variants. The box plots depict the median and interquartile range, with the vertical black lines displaying the minimum to maximum. ^a P < .0001.

underpowered to detect an association between the LDL-C polygenic score and risk of CVD events among individuals of African genetic ancestry (test for trend, P = .75; n = 4972) (eFigure 4 in the Supplement).

Estimated Prevalence of Monogenic FH in the UK Biobank Cohort

Data from the cohort of 48 741 individuals with genotyping array and exome sequencing data in the UK Biobank were used to compare polygenic and monogenic causes of FH (Figure 1 and eTables 5 and 6 in the Supplement). A predicted FH-associated variant was identified in 277 individuals, representing a prevalence of 0.57% (1 in 176 individuals). Individuals with monogenic FH had statistically significantly higher LDL-C levels than those without an FH-associated variant (mean [SD] LDL-C, 161.15 [49.1] mg/dL vs 140.2 [34.0] mg/dL; *P* < .001) (**Figure 3**A and eTable 6 in the Supplement). The LDL-C levels were not statistically significantly different between individuals carrying a bioinformatically predicted FH-associated variant (variant variant) as carrying a bioinformatically predicted FH-associated variant) variant (variant) variant) (Figure 3A and eTable 6 in the Supplement).

ant compared with those carrying variants annotated in ClinVar as likely pathogenic or pathogenic for FH (mean [SD] LDL-C, 155.6 [39.7] mg/dL vs 167.4 [57.5] mg/dL; P = .38) (Figure 3B). Furthermore, the risk of premature CVD events (at 55 years or younger) was comparable in individuals carrying predicted FHassociated variants vs those carrying FH-associated variants reported in ClinVar (unadjusted HR, 3.05 [95% CI, 1.58-5.89] vs 3.05 [95% CI, 1.52-6.12]; P = .002). Pairwise comparison of Peto and Peto tests with Benjamini-Hochberg correction is shown in eFigures 5 and 6 in the Supplement.

Overall, monogenic FH-associated variants were found in *LDLR* for 257 individuals (92.9%), *PCSK9* for 13 (4.7%), and *APOB* for 7 individuals (2.5%). A total of 121 unique monogenic FH-associated variants were identified, most of which were in the *LDLR* gene (110 of 121 [90.9%]) (eTable 5 in the **Supplement**). None of the participants had homozygous FH; however, 2 participants carried 2 different FH-associated variants in *LDLR*.

Monogenic FH and Premature CVD

Monogenic FH was associated with a statistically significantly greater risk of CVD vs individuals without an FH-associated variant (Peto and Peto test, $\chi^2 = 9.7$ on 1 *df*; *P* = .002) (eFigure 6 in the Supplement). The aHR for a composite CVD event among those with monogenic FH was 1.78 compared with that among those without a monogenic FH-associated variant (95% CI, 1.28-2.48; *P* < .001). This difference was most notable for premature CVD events (at 55 years or younger) in which there was a statistically significant enrichment for individuals with monogenic FH vs those without (17 of 277 [6.1%] vs 988 of 48 464 [2.0%]) (HR, 3.17; 95% CI, 1.96-5.12; *P* < .001).

Next, we investigated whether there were differences in the risk of CVD events among participants with monogenic FH, polygenic hypercholesterolemia (>95th percentile of polygenic score), or nongenetic hypercholesterolemia at comparable levels of LDL-C. For this, participants were grouped based on their LDL-C levels. In this analysis, median LDL-C levels did not significantly differ among the monogenic, polygenic, and nongenetic hypercholesterolemia groups at study enrollment (Figure 4A). Characteristics of the participants stratified by these subgroups are provided in the Table. There was a significant, stepwise trend toward a greater risk of CVD among individuals with nongenetic hypercholesterolemia, polygenic hypercholesterolemia, and monogenic FH (Peto and Peto test for trend: HR, 1.93; 95% CI, 1.34-2.77; P < .001) (Figure 4B and C). Participants with monogenic FH had a significantly greater risk of CVD than those with polygenic hypercholesterolemia (pairwise comparison of Peto and Peto tests with Benjamini-Hochberg correction: aHR, 1.26; 95% CI, 1.03-1.55; P = .03) (Figure 4B and C). These results remained unaltered when HRs were also adjusted for LDL-C levels measured at study enrollment (Figure 4C). These data suggest that genetic contributions to hypercholesterolemia significantly increase CVD risk.

Underdiagnosed and Undertreated Hypercholesterolemia

Individuals with monogenic FH were significantly more likely than those without a monogenic FH-associated variant to be receiving cholesterol-lowering medication at the time of

Figure 4. Monogenic Familial Hypercholesterolemia (FH) vs Polygenic Hypercholesterolemia and Cardiovascular Disease (CVD) Events



A, Boxplots display the median, interquartile range, and minimum to maximum of direct low-density lipoprotein cholesterol (LDL-C) levels (to convert to millimoles per liter, multiply by 0 0259) that are adjusted for cholesterol-lowering medication among individuals with monogenic FH (mono+), polygenic hypercholesterolemia (poly+; 223 single-nucleotide variants LDL-C polygenic score >95th percentile), and individuals with hypercholesterolemia of no known genetic cause (LDL+). B, Time-to-first-event analyses are depicted for composite CVD events, including myocardial infarction, coronary or carotid revascularization, ischemic stroke, or all-cause mortality. Individuals were stratified based on the rank order groupings of nongenetic hypercholesterolemia. polygenic hypercholesterolemia, or monogenic FH. C, Hazard ratios (HRs) with 95% CIs are displayed for composite CVD events with or without adjustment for LDL-C levels. All HRs were adjusted for age, sex, genotyping array or batch, and the first 4 principal components of ancestry.

enrollment (36.3% [57 of 157] vs 12.6% [3309 of 26245]; P < .001). However, among individuals with monogenic FH and severe hypercholesterolemia (LDL-C level \geq 193.35 mg/dL), 34.3% (12 of 35) of individuals were not receiving cholesterollowering medication and 40.0% (14 of 35) were seemingly unaware of their high cholesterol level at enrollment (high cholesterol level was not reported at enrollment). Undertreatment of severe hypercholesterolemia was even more notable among individuals who did not have monogenic FH, with 71.7% (1426 of 1990) of these individuals not receiving cholesterollowering medication at enrollment and 75.4% (1521 of 1990) unaware of their high cholesterol level.

Follow-up lipid levels were available for 128 of 1438 individuals who had severe hypercholesterolemia and were not taking cholesterol-lowering medication at study enrollment. After a mean follow-up of 3 years, only 22.7% (29 of 128) of these individuals reported taking cholesterol-lowering medication. The 99 individuals who remained untreated had a mean (SD) follow-up LDL-C level of 257.70 (22.91) mg/dL. In contrast, the mean (SD) LDL-C level of 29 individuals who had received cholesterol-lowering treatment since enrollment was 130.08 (22.76) mg/dL and all individuals had an LDL-C level of less than 193.35 mg/dL (eFigure 7 in the Supplement). These real-world data indicate the need for better recognition and management of severe hypercholesterolemia and FH.

jamacardiology.com

Discussion

The present study reports that a monogenic FH-associated variant is present in 1 in 176 (0.57%) participants from the UK Biobank exome sequencing cohort²⁵ and is associated with elevated levels of LDL-C and increased risk of premature CVD. At comparable levels of LDL-C, both monogenic FH and polygenic hypercholesterolemia appeared to be associated with significantly increased risk of CVD events compared with hypercholesterolemia with no identified genetic cause, with monogenic FH associated with the greatest risk. These data suggest that the mechanism underlying hypercholesterolemia and the measured level of LDL-C contribute to CVD risk, which underscores the importance of ascertaining the causes of hypercholesterolemia to accurately assess risk.

We found that monogenic FH and polygenic hypercholesterolemia are associated with greater risk of CVD than hypercholesterolemia without a known genetic cause. Consistent with previous studies, we believe our data demonstrated that an elevated LDL-C polygenic score is associated with a moderate increase in CVD risk in both the overall population and in individuals with hypercholesterolemia.^{17,18} These findings are consistent with those of a previous report that found that monogenic FH was associated with significantly greater CVD Table. Baseline Characteristics of UK Biobank Participants in the Exome Sequencing Cohort Stratified by Cause of Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Levels

	No. (%) ^a				
Characteristic	Nongenetic Hypercholesterolemia (n = 2232)	Polygenic Hypercholesterolemia (n = 2379)	Monogenic Hypercholesterolemia (n = 277)	P Value	
Age, mean (SD), y	56.3 (7.8)	56.4 (8.0)	57.1 (7.9)	.25	
Sex, female	1216 (54.5)	1314 (55.2)	157 (56.7)	.74	
Ancestry					
European	2153 (96.5)	2281 (95.9)	260 (93.9)	.10	
East Asian	53 (2.4)	60 (2.5)	11 (3.9)	.28	
African	26 (1.2)	38 (1.6)	6 (2.2)	.27	
Biochemistry					
Total cholesterol, mg/dL, mean (SD)	237.33 (46.44)	236.35 (48.31)	232.91 (57.43)	.08	
No. of patients	2232	2237	257	NA	
Direct LDL-C, mg/dL, mean (SD)	155.36 (37.25)	155.71 (37.57)	161.15 (49.14)	.40	
No. of patients	2232	2232	256	NA	
Apolipoprotein B, mg/dL, mean (SD)	112.62 (25.05)	113.17 (25.73)	110.86 (26.78)	.40	
No. of patients	2218	2223	253	NA	
Triglycerides, mg/dL, mean (SD)	161.22 (87.15)	158.99 (96.38)	134.55 (75.22)	<.001	
No. of patients	2228	2233	255	NA	
HDL-C, mg/dL, mean (SD)	57.17 (14.58)	57.02 (15.04)	57.40 (14.58)	.69	
No. of patients	2101	2114	244	NA	
Apolipoprotein A1, mg/dL, mean (SD)	155.82 (27.05)	154.83 (27.14)	152.83 (25.8)	.24	
No. of patients	2090	2103	244	NA	
Lipoprotein(a), mg/dL, mean (SD)	19.91 (21.25)	18.32 (20.45)	18.86 (18.74)	.09	
No. of patients	1778	1787	194	NA	
Hemoglobin A _{1c} , %	5.43 (0.53)	5.45 (0.60)	5.48 (0.56)	.26	
No. of patients	2094	2221	257	NA	
C-reactive protein, mg/dL, mean (SD)	0.25 (0.38)	0.23 (0.39)	0.25 (0.44)	<.001	
No. of patients	2227	2228	255	NA	
Physical examination					
BMI, mean (SD), kg/m ²	27.60 (4.64)	27.40 (4.97)	27.59 (4.97)	.04	
No. of patients	2230	2375	276	NA	
Medical history, No. of patients/total No. (%)					
Angina	37/2230 (1.7)	87/2376 (3.7)	16/275 (5.8)	<.001	
Myocardial infarction	29/2230 (1.30)	54/2376 (2.3)	17/275 (6.2)	<.001	
Ischemic stroke	15/2230 (0.7)	34/2376 (1.5)	3/275 (0.1)	.04	
Hypertension	542/2230 (24.3)	612/2376 (25.8)	73/275 (26.6)	.45	
Diabetes	85/2228 (3.8)	124/2375 (5.2)	16/277 (5.8)	.05	
Current smoker	208/2225 (9.4)	217/2373 (9.1)	16/277 (5.8)	.14	
Medications, No. of patients/total No. (%)					
Cholesterol-lowering medication	178/1210 (14.7)	247/1307 (18.9)	57/157 (36.3)	<.001	
Antihypertensives	194/1210 (16.0)	213/1307 (16.3)	34/157 (21.7)	.20	
Insulin	9/1210 (0.7)	8/1307 (0.6)	0/157 (0)	.54	
Exogenous hormones	110/1210 (9.1)	148/1307 (11.3)	8/157 (5.1)	.20	

Abbreviations: BMI, body mass index (calculated as the weight in kilograms divided by height in meters squared); HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; SNV, single-nucleotide variants.

SI conversion factors: To convert total cholesterol, LDL-C, HDL-C to millimoles per liter, multiply by 0.0259; apolipoprotein A1 and apolipoprotein B to grams per liter, multiply by 0.01; triglycerides to millimoles per liter, multiply by 0.0113; to convert lipoprotein(a) to micromoles to liter, multiply by 0.0357; and C-reactive protein to nanomoles per liter, multiply by 9.524.

^a Individuals were grouped on the basis of LDL-C levels. Polygenic hypercholesterolemia is defined as an LDL-C polygenic score greater than the 95th percentile within a genetic superpopulation using a 223 SNV score.

risk than polygenic hypercholesterolemia at similar levels of LDL-C measured at study enrollment.²² One possible explanation for the increased risk is that monogenic hypercholesterolemia may manifest earlier in life than either polygenic hypercholesterolemia or hypercholesterolemia with no identified genetic cause, leading to greater cumulative LDL-C exposure.^{3,35} Although it is not possible to directly test this hypothesis in the UK Biobank cohort because of the absence

of longitudinal lipid levels, we noted that 60.0% of individuals with monogenic hypercholesterolemia compared with 24.6% of individuals with polygenic hypercholesterolemia reported a history of high cholesterol at the time of enrollment to the UK Biobank study, which may be consistent with earlier manifestation of hypercholesterolemia in those with a monogenic cause. It is also possible that polygenic hypercholesterolemia responds better than monogenic FH to pharmacological management strategies such as cholesterol-lowering medication.

We estimated that 1 in 176 individuals from the UK Biobank cohort carried an FH-associated variant. This estimate is slightly higher than in other studies that have estimated the prevalence of FH to be in the range of 1 in 217 to 250 people.^{1,2,36} A reason for potential overestimation of the prevalence of monogenic FH is the challenge in classifying the pathogenicity of missense variants. We sought to mitigate the risk of overclassification by requiring at least 5 of 6 bioinformatic tools to predict that a missense variant was pathogenic. Furthermore, we observed that bioinformatically predicted FHassociated variants were associated with comparable LDL-C levels and similar risk of premature CVD compared with variants with likely pathogenic or pathogenic annotations in ClinVar.37,38 Of note, we found that many individuals with variants annotated as pathogenic for FH did not display severe hypercholesterolemia. The incomplete penetrance of FH variants we observed in the UK Biobank cohort may reflect the healthy volunteer selection bias of the participants in this cohort compared with studies of FH patients recruited from cardiology or lipid clinics.^{39,40} The results from the present study appear to highlight an important challenge to the diagnosis and treatment of individuals with monogenic FH. Future research will be required to assess how genetic background and environmental factors modulate the phenotype of monogenic FH. The finding that 2497 individuals from the exome sequencing cohort had LDL-C levels greater than 193.35 mg/dL and had neither a monogenic nor polygenic explanation for this phenotype suggests the presence of other genetic or geneenvironment causes for severe hypercholesterolemia that remain to be identified.41

Our findings also support the possible need for routine genetic testing of patients with clinically suspected FH to reduce the incidence of premature CVD observed among individuals with monogenic FH.^{3,6,42,43} The autosomal codominant inheritance of monogenic FH-associated variants enables clinicians to efficiently screen relatives of probands in a process known as cascade screening.⁴⁴⁻⁴⁶ Cascade screening facilitates early diagnosis and initiation of lifestyle modification⁴⁷ and cholesterol-lowering medication.^{4,48,49} Individuals with monogenic FH have the highest risk of CVD^{3,50} and are likely to derive the most benefit from statin and ezetimibe therapy, and, if needed, more costly cholesterol-lowering medications such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.⁵¹⁻⁵³

Limitations

This study has some limitations. First, data on cholesterollowering medication at enrollment and pretreatment lipid profiles were not available for all individuals; therefore, we used pretreatment LDL-C levels in these individuals.^{1,26} Furthermore, longitudinal data for lipid levels were not available for most participants in the UK Biobank cohort. Second, detailed characteristics needed for deep phenotyping of FH, such as thorough family history of CVD and physical examination findings suggestive of hypercholesterolemia, were not available for participants in the UK Biobank cohort. Third, the UK Biobank cohort was predominantly composed of individuals with British white genetic ancestry and individuals of non-European ancestry were underrepresented. In addition, we did not assess LDLR copy number and larger insertion or deletion variants, which are believed to be causative for approximately 5% of clinical FH cases.⁵⁴⁻⁵⁶ We used a polygenic risk score composed of 223 SNVs. Larger, genome-wide scores composed of millions of SNVs may provide incremental improvements in risk prediction.21

Conclusions

Monogenic FH and polygenic hypercholesterolemia were associated with an increased CVD risk compared with hypercholesterolemia without an identifiable genetic cause, with monogenic FH associated with the greatest risk. These results suggest that a possible genetic cause of hypercholesterolemia is associated with CVD risk and underscores the importance of genetic profiling to better stratify risk in patients.

ARTICLE INFORMATION

Accepted for Publication: December 1, 2019.

Published Online: February 12, 2020. doi:10.1001/jamacardio.2019.5954

Correction: This article was corrected on March 11, 2020, to fix the key in Figure 3A.

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Trinder M et al. *JAMA Cardiology*.

Author Contributions: Mr Trinder and Dr Brunham had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Concept and design:* Trinder, Brunham. *Acquisition, analysis, or interpretation of data:* All authors.

jamacardiology.com

Drafting of the manuscript: Trinder, Brunham. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Trinder. Obtained funding: Brunham. Administrative, technical, or material support: Trinder, Francis. Supervision: Brunham.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by a Sector Improvement Project award from Genome British Columbia.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data: preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Information: Mr Trinder is supported by a Vanier Canada Graduate Scholarship. Dr Brunham is a Michael Smith Foundation for Health Research scholar, and a Canada Research Chair in Precision Cardiovascular Disease Prevention.

Additional Contributions: The authors would like to acknowledge the participants and individuals involved in establishing the UK Biobank project, Global Lipid Genetics Consortium, and Compute Canada and others involved in establishing the computational resources, tools, and support for this project.

REFERENCES

1. Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. *Eur Heart J.* 2016;37(17):1384-1394. doi:10.1093/ eurheart/jehw028

2. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. *BMJ Open*. 2017;7(9):e016461. doi:10.1136/bmjopen-2017-016461

3. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. *J Am Coll Cardiol*. 2016;67 (22):2578-2589. doi:10.1016/j.jacc.2016.03.520

4. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. *Nat Rev Dis Primers*. 2017;3: 17093. doi:10.1038/nrdp.2017.93

5. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2017;38(32): 2459-2472. doi:10.1093/eurheartj/ehx144

6. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. *Eur Heart J.* 2017;38(20):1573-1579. doi:10.1093/eurhearti/ehx004

7. Nordestgaard BG, Chapman MJ, Humphries SE, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J.* 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273

8. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. *Clin Genet*. 2010;77(6):572-580. doi:10.1111/j.1399-0004.2009.01356.x

9. Mozas P, Castillo S, Tejedor D, et al. Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR. *Hum Mutat*. 2004;24(2):187. doi:10.1002/humu.9264

10. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. *Am J Cardiol*. 2008;102(9):1187-1193, 1193.e1. doi:10.1016/j.amjcard. 2008.06.056

11. Ajufo E, Cuchel M. Improving the yield of genetic testing in familial hypercholesterolaemia. *Eur Heart J.* 2017;38(8):574-576. doi:10.1093/eurheartj/ehw166

12. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. *Atherosclerosis*. 2005;180(1): 155-160. doi:10.1016/j.atherosclerosis.2004.12.001

13. Shin DG, Han SM, Kim DI, et al. Clinical features of familial hypercholesterolemia in Korea: predictors of pathogenic mutations and coronary artery disease—a study supported by the Korean Society of Lipidology and Atherosclerosis. *Atherosclerosis*. 2015;243(1):53-58. doi:10.1016/j.atherosclerosis.2015.08.033

14. Clarke RE, Padayachee ST, Preston R, et al. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. *Heart*. 2013;99(3): 175-180. doi:10.1136/heartjnl-2012-302917

 Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. *Arterioscler Thromb Vasc Biol*. 2016;36(12):2439-2445. doi:10.1161/ATVBAHA.116. 308027

16. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. *Lancet*. 2013;381(9874):1293-1301. doi:10.1016/S0140-6736(12)62127-8

17. Willer CJ, Schmidt EM, Sengupta S, et al; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45(11):1274-1283. doi:10.1038/ng.2797

18. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N Engl J Med*. 2008;358 (12):1240-1249. doi:10.1056/NEJMoa0706728

19. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol*. 2012;60 (25):2631-2639. doi:10.1016/j.jacc.2012.09.017

20. Klarin D, Damrauer SM, Cho K, et al; Global Lipids Genetics Consortium; Myocardial Infarction Genetics (MIGen) Consortium; Geisinger-Regeneron DiscovEHR Collaboration; VA Million Veteran Program. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nat Genet*. 2018;50(11):1514-1523. doi:10.1038/s41588-018-0222-9

21. Natarajan P, Peloso GM, Zekavat SM, et al; NHLBI TOPMed Lipids Working Group. Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. *Nat Commun.* 2018;9(1):3391. doi:10.1038/s41467-018-05747-8

22. Trinder M, Li X, DeCastro ML, et al. Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia. *J Am Coll Cardiol*. 2019;74 (4):512-522. doi:10.1016/j.jacc.2019.05.043

23. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z

24. Band G, Marchini J. BGEN: a binary file format for imputed genotype and haplotype data. *bioRxiv*. 2018;308296. doi:10.1101/308296

25. van Hout CV, Tachmazidou I, Backman JD, et al. Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK Biobank. *bioRxiv*. 2019;572347. doi:10.1101/572347

26. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). *Am J Cardiol*. 2003;92(2):152-160. doi:10.1016/S0002-9149(03)00530-7

27. Lu X, Peloso GM, Liu DJ, et al; GLGC Consortium. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery disease. *Nat Genet*. 2017;49(12):1722-1730. doi:10.1038/ng.3978

28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81(3):559-575. doi:10.1086/519795

29. Cingolani P, Platts A, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Fly (Austin)*. 2012;6(2):80-92. doi:10.4161/fly.19695

30. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. *Hum Mutat*. 2013;34(9):E2393-E2402. doi:10.1002/ humu.22376

31. Liu X, Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Hum Mutat*. 2016;37(3):235-241. doi:10.1002/humu.22932

32. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res.* 2014;42(Database issue):D980-D985. doi:10.1093/ nar/gkt1113

33. Cingolani P, Patel VM, Coon M, et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. *Front Genet*. 2012;3:35. doi:10.3389/fgene. 2012.00035

34. Do R, Stitziel NO, Won HH, et al; NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature*. 2015;518(7537):102-106. doi:10.1038/nature13917

35. Sharifi M, Higginson E, Bos S, et al. Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. *Atherosclerosis*. 2017;263: 405-411. doi:10.1016/j.atherosclerosis.2017.05.015

36. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). *Circulation*. 2016; 133(11):1067-1072. doi:10.1161/CIRCULATIONAHA.115. 018791

37. Hopkins PN, Lane SR. Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. *Curr Opin Lipidol*. 2017; 28(2):144-151. doi:10.1097/MOL. 00000000000397

38. Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. *Nat Rev Cardiol*. 2019;16(1):9-20. doi:10.1038/s41569-018-0052-6

39. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population.

Am J Epidemiol. 2017;186(9):1026-1034. doi:10.1093/aje/kwx246

40. Mszar R, Grandhi GR, Valero-Elizondo J, et al. Absence of coronary artery calcification in middle aged familial hypercholesterolemia patients without atherosclerotic cardiovascular disease [published online November 11, 2019]. *JACC Cardiovasc Imaging*. doi:10.1016/j.jcmg.2019.11.001

41. Oetjens MT, Kelly MA, Sturm AC, Martin CL, Ledbetter DH. Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders. *Nat Commun.* 2019;10(1):4897. doi:10.1038/s41467-019-12869-0

42. Sturm AC, Knowles JW, Gidding SS, et al; Convened by the Familial Hypercholesterolemia Foundation. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. *J Am Coll Cardiol*. 2018;72(6):662-680. doi:10.1016/ j.jacc.2018.05.044

43. Nordestgaard BG, Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? *Eur Heart J.* 2017;38(20):1580-1583. doi:10.1093/eurheartj/ehx136

44. Knowles JW, Rader DJ, Khoury MJ. Cascade screening for familial hypercholesterolemia and the use of genetic testing. *JAMA*. 2017;318(4):381-382. doi:10.1001/jama.2017.8543

45. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Cost effectiveness

analysis of different approaches of screening for familial hypercholesterolaemia. *BMJ*. 2002;324 (7349):1303. doi:10.1136/bmj.324.7349.1303

46. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child-parent familial hypercholesterolemia screening in primary care. *N Engl J Med*. 2016;375(17):1628-1637. doi:10.1056/ NEJMoa1602777

47. Khera AV, Emdin CA, Drake I, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. *N Engl J Med*. 2016;375(24):2349-2358. doi:10.1056/NEJMoa1605086

48. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. *BMJ*. 2008;337:a2423. doi:10.1136/bmj.a2423

49. Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. *N Engl J Med*. 2019;381(16): 1547-1556. doi:10.1056/NEJMoa1816454

50. Bourbon M, Alves AC, Alonso R, et al. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. *Atherosclerosis*. 2017;262: 8-13. doi:10.1016/j.atherosclerosis.2017.04.002

51. Ellis KL, Pang J, Schultz CJ, Watts GF. New data on familial hypercholesterolaemia and acute coronary syndromes: the promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. *Eur J Prev Cardiol*. 2017;24(11):1200-1205. doi:10.1177/2047487317708890

52. Ray KK, Bays HE, Catapano AL, et al; CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med*. 2019; 380(11):1022-1032. doi:10.1056/NEJMoa1803917

53. Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. *Circ Cardiovasc Qual Outcomes*. 2019;12(8):e005404. doi:10.1161/ CIRCOUTCOMES.118.005404

54. Wang J, Ban MR, Hegele RA. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. *J Lipid Res.* 2005;46(2): 366-372. doi:10.1194/jlr.D400030-JLR200

55. lacocca MA, Wang J, Dron JS, et al. Use of next-generation sequencing to detect *LDLR* gene copy number variation in familial hypercholesterolemia. *J Lipid Res.* 2017;58(11):2202-2209. doi:10.1194/jlr.D079301

56. Taylor A, Martin B, Wang D, Patel K, Humphries SE, Norbury G. Multiplex ligation-dependent probe amplification analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia. *Clin Genet*. 2009; 76(1):69-75. doi:10.1111/j.1399-0004.2009.01168.x

Editor's Note

Opportunities and Challenges for Polygenic Risk Scores in Prognostication and Prevention of Cardiovascular Disease

Christopher J. O'Donnell, MD, MPH

Lowering low-density lipoprotein cholesterol (LDL-C) levels remains a mainstay of cardiovascular disease prevention, but gaps in treatment remain, even in persons with hyperchol-

←

Related article page 390

esterolemia and greatly elevated LDL-C levels. Although well-described gene variants in the apolipopro-

tein B (APOB), low-density lipoprotein receptor (LDLR), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes explain small but important fractions of monogenic hypercholesterolemia, recent attention has turned to prognostication of cardiovascular disease using polygenic risk scores (PRS) that incorporate common genetic variants derived from largescale genome-wide association studies of lipid subfractions. Earlier PRS considered only variants with genome-wide significance, and newer studies have focused on methods that better capture the variance conferred by millions of variants, suggesting an ability to identify risk equivalent to monogenic mutations.¹ There remains a gap in evidence from prospective observational studies or treatment trials regarding the appropriate placement of PRS in risk assessment and lipid treatment decisions relative to information on rare monogenic gene variants, particularly in multiethnic populations.

In this issue of *JAMA Cardiology*, Trinder et al² report analyses of large-scale population genomic data, including wholeexome sequence and individual-level genotypic and lipidphenotypic data from 48 741 participants of European descent in the UK Biobank, in which 277 individuals (0.57% [1:176]) harbor a monogenic variant for hypercholesterolemia. In this European-descent population, relative to the reference group of individuals with nongenetic hypercholesterolemia, the adjusted hazard ratios for a cardiovascular disease event were 1.26 (95% CI, 1.03-1.55; P = .03) for individuals with polygenic hypercholesterolemia (>95th percentile of PRS) and 1.93 (95% CI, 1.34-2.77; P < .001) in participants with familial hypercholesterolemia, perhaps reflecting a stronger association of lifelong exposure with monogenic vs polygenic hypercholesterolemia.

Emerging evidence suggests that a PRS incorporating millions of gene variants may modify the risk conferred by monogenic variants.³ A fundamental question unanswered by the current study is whether risk levels from PRS, monogenic risk, or both together offer incremental value over and above LDL-C levels and burden of cardiovascular disease risk. Nevertheless, this study represents among the first prospective studies of cardiovascular disease comparing PRS vs monogenic risk in a population with genome sequences. The modest statistical significance in this study reflects the small sample sizes examined.

However, the findings point to questions to be addressed in future genome-sequencing studies in large biobanks. Which PRS algorithms should be used in risk assessment and

jamacardiology.com